Posts Tagged ‘janus kinase’

July 9, 2012

Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

Tofacitinib is the first in a new class of immunosuppressive agents that inhibit janus kinase, an important transcription factor. This randomized-controlled trial compared tofacitinib to cyclosporine in renal transplant patients. Tofacitinib showed lower rates of acute rejection and chronic changes on biopsy, with better renal function compared to a cyclosporine-based regimen. On the other hand, […]

No Comments Posted in Renal Transplantation